These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16167270)

  • 1. [Infant dies of invasive pneumococcal disease].
    Sitzmann FC
    Klin Padiatr; 2005; 217(5):251-2. PubMed ID: 16167270
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
    Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of invasive pneumococcal infection in children].
    Sáez-Llorens X
    An Esp Pediatr; 2002 Nov; 57(5):391-3. PubMed ID: 12467540
    [No Abstract]   [Full Text] [Related]  

  • 4. Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005.
    Harboe ZB; Valentiner-Branth P; Benfield TL; Christensen JJ; Hjuler T; Kaltoft M; Krogfelt KA; Lambertsen L; Konradsen HB
    Vaccine; 2008 Jul; 26(29-30):3765-71. PubMed ID: 18513840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany.
    Rückinger S; van der Linden M; Reinert RR; von Kries R; Burckhardt F; Siedler A
    Vaccine; 2009 Jun; 27(31):4136-41. PubMed ID: 19406190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong.
    Ho PL; Chiu SS; Chow FK; Mak GC; Lau YL
    Vaccine; 2007 Sep; 25(39-40):6837-41. PubMed ID: 17714837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
    Rose M; Zielen S
    Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of invasive pneumococcal disease after introduction of the Universal Infant Immunization Program, British Columbia (2002-2005).
    Can Commun Dis Rep; 2006 Jul; 32(14):157-61. PubMed ID: 16869067
    [No Abstract]   [Full Text] [Related]  

  • 9. Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997-2006.
    Motlova J; Benes C; Kriz P
    Epidemiol Infect; 2009 Apr; 137(4):562-9. PubMed ID: 18796171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA.
    Grijalva CG; Griffin MR
    Expert Rev Vaccines; 2008 Feb; 7(1):83-95. PubMed ID: 18251696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of invasive pneumococcal disease in HIV-infected children: expanding the toolbox.
    Abzug MJ; Pelton SI
    J Infect Dis; 2009 Apr; 199(8):1109-11. PubMed ID: 19265480
    [No Abstract]   [Full Text] [Related]  

  • 13. The shifting dynamics of pneumococcal invasive disease after the introduction of the pneumococcal 7-valent conjugated vaccine: toward the new pneumococcal conjugated vaccines.
    Greenberg D
    Clin Infect Dis; 2009 Jul; 49(2):213-5. PubMed ID: 19508164
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of pneumococcal conjugate vaccine in Greater Vancouver, Canada: 2004-2005.
    Bjornson G; Scheifele DW; Bettinger J; Patrick DM; Gustafson L; Daly P; Tyrrell GJ
    Pediatr Infect Dis J; 2007 Jun; 26(6):540-2. PubMed ID: 17529875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].
    de Greeff SC; Sanders EA; de Melker HE; van der Ende A; Vermeer PE; Schouls LM
    Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1454-7. PubMed ID: 17633974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing epidemiology of invasive pneumococcal disease: a complicated story.
    Black S
    Clin Infect Dis; 2008 Aug; 47(4):485-6. PubMed ID: 18627248
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pneumococcal infections. Every second fatality within 48 hours].
    MMW Fortschr Med; 2001 Nov; 143(47):60. PubMed ID: 11791369
    [No Abstract]   [Full Text] [Related]  

  • 18. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
    Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expected benefits of pneumococcal vaccination in Canadian infants and children < 5 years old.
    Can Commun Dis Rep; 2006 Mar; 32(5):45-54. PubMed ID: 16649291
    [No Abstract]   [Full Text] [Related]  

  • 20. Understanding the link between pneumococcal serotypes and invasive disease.
    Soley C; Arguedas A
    Vaccine; 2009 Aug; 27 Suppl 3():C19-21. PubMed ID: 19535183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.